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tin (8, 9) . Implantation and pituitary organ culture methods have been used to show that dopamine inhibits prolactin secretion and, apomorphine, a dopamine agonist, mimics the dopamine effect (10, 11). Conversely, estrogen administration in viuo increases serum prolactin levels (12-16). Raymond et al. (17) [3H]Spiroperidol binding was measured by a modification of the method of Creese et al. (32) . The animals were decapitated at 2 to 3 weeks after surgery and the anterior pituitaries were quickly removed and homogenized in Krebs' bicarbonate buffer (124 mM NaCl, 5 mM KCl, 26 mM NaHC03, 1.2 mu KH2P04, 1.3 mM MgSO*, and 0.75 mu CaC12), pH 7.4, at 4°C (100 volumes, w/v) with a glass-glass homogenizer and centrifuged twice at 4'C for 15 min at 28,000 x g to obtain crude membrane pellets. The final suspension was in Krebs' bicarbonate buffer containing 0.1% ascorbic acid with 1.2 pituitary eq/ml ("1 mg of protein/ml). Incubations were performed in l-ml volume of membrane suspension with [3H]spiroperidol (New England Nuclear, Chicago, IL, specific activity 24 Ci/mmol) for 15 min at 37°C. The [3H]spiroperidol was greater than 98% pure as assessed by thin layer chromatography on silica gel using a solvent system of methanol, benzene, water (15:2:5). The membranes were collected by rapid filtration over Whatman GF/B filters and rinsed with 15 ml (3 x 5 ml) of ice cold Kreb's bicarbonate buffer. The amount of radioactivity retained on the filter was determined by liquid scintillation spectrometry at 55% eff? ciency. 0.1% ascorbic acid and prepared immediately prior to each experiment. In some cases, the steroids were further purified by thin layer chromatography using a solvent system of cyclohexane, chloroform, and acetic acid (40:40:3) as described by Stubenrauch et al. (33) . This system separates P-hydroxyestradiol from the other estrogen derivatives. Fig. 1 
Bound and free radioactivity were separated by filtration as described in the text. The results are expressed as a percentage of the total specific binding in the absence of any inhibitor. KI values were determined using the formula: KI = Z&/(1 + C/KU) where the If& is the concentration of the drug required to inhibit 50% of the specific binding (determined by log probit plots), c is the concentration of [aH]spiroperidol, and KD its dissociation constant (34) (12) (13) (14) (15) (16) , and pretreatment of cultured anterior pituitary cells with 17/?-estradiol is sufficient to antagonize the prolactin inhibitory effect of dopamine (17). In our system, 17/I-estradiol had no effect on the dopamine receptor; however, since enzymes capable of converting 17P-estradiol to 2-hydroxyestradiol have been described in pituitary tissue (35, 36) , we cannot exclude the possibility that the observed inhibitory effect of estradiol on dopamine is the result of an antagonistic effect of 2-hydroxyestradiol on dopamine receptors. Recent results from our laboratory indicate that during a 5-h incubation, 2-hydroxyestradiol (lo-" M) antagonized the inhibitory effect of either dopamine or 2-bromo-a-ergocryptine on prolactin release from cultured anterior pituitary cells2 Furthermore, the present study raises the possibility that other responses to 17P-estradiol in the central nervous system may be mediated by 2-hydroxyestradiol, since catecholestrogen-forming enzymes have been found in many brain areas (35) (36) (37) . Our study, however, does not exclude the possibility that I7P-estradiol may regulate pituitary prolactin production via a mechanism other than interference with dopamine binding (38) . In conclusion, this work demonstrates that 2-hydroxyestradiol, in addition to its estrogenic properties, may have a role in the regulation of prolactin secretion by direct interaction with dopamine receptors in the anterior pituitary.
